98105-99-8
98105-99-8
Chemical Structure
Sarafloxacin
Synonym(s): A-56620
- CAS No.: 98105-99-8
- Formula:C20H17F2N3O3
- Molecular Weight:385.36
IUPAC Name: 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
InChIKey: XBHBWNFJWIASRO-UHFFFAOYSA-N
SMILES: O=C(C1=CN(C2=CC=C(F)C=C2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Biological Activity: Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sarafloxacin | 98.43% | Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarafloxacin (Standard) | ≥98% | Sarafloxacin (Standard) (A-56620 (Standard)) is the analytical standard of Sarafloxacin (HY-B0343). This product is intended for research and analytical applications. Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarafloxacin-d8 | Sarafloxacin-d8 (A-56620-d8) is the d8 labeled Sarafloxacin (HY-B0343). Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. McConville ML, et al. Effects of sarafloxacin hydrochloride on human enteric bacteria under simulated human gut conditions. Vet Q. 1995;17(1):1-5. [Content Brief]
- [2]. Fernandes CJ, et al. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates. Chemotherapy. 1988;34(3):216-228. [Content Brief]
